LifeMD Appoints Veteran Healthcare Finance Executive Atul Kavthekar as New CFO; Expands Leadership Team
LFMD sits 59% above its 52-week low of $2.56.
Summary
LifeMD announced the departure of its CFO, Marc Benathen, and the immediate appointment of Atul Kavthekar, a seasoned healthcare finance executive, as his successor. The company also promoted Jessica Friedeman to Chief Business Officer and Chris Pisano to Chief Marketing Officer.
Key Events · Executive and Board Changes · LFMD
-
CFO Departure
Marc Benathen resigned as Chief Financial Officer, effective March 31, 2026, to pursue a new opportunity. He will provide transition services for six to twelve months at a fee of $38,117 per month.
-
New CFO Appointment
Atul Kavthekar was appointed Chief Financial Officer, effective March 16, 2026. He brings nearly three decades of executive leadership and financial expertise spanning provider-side healthcare, retail and specialty pharmacy, and e-commerce.
-
Significant Equity Grant for New CFO
As a material inducement to his employment, Mr. Kavthekar will be granted 675,000 restricted stock units (RSUs), with 337,500 time-based and 337,500 performance-based.
-
Leadership Team Expansion
Jessica Friedeman was promoted to Chief Business Officer and Chris Pisano to Chief Marketing Officer, further strengthening the executive leadership team.
Analysis · LFMD · Industrial Applications And Services
This filing details significant leadership changes at LifeMD, occurring shortly after the company disclosed a financial restatement and material weaknesses in its internal controls in its recent 10-K. While the departure of CFO Marc Benathen is a notable event, the immediate appointment of Atul Kavthekar, who brings extensive experience in healthcare, M&A, and building scalable financial infrastructure, is a strong positive signal. His substantial RSU grant (valued at approximately $2.75 million, representing about 1.4% of the company's market cap) aligns his incentives with long-term shareholder value. The additional promotions of Jessica Friedeman and Chris Pisano further strengthen the executive team, indicating a proactive effort to address operational and strategic growth following recent financial challenges. Investors should view these changes as a strategic move to stabilize and enhance the company's financial and operational leadership.
How filings like this one have moved
In the 30 days to Oct 5, 2026, 36.9% of the 964 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.65%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, LFMD was trading at $4.08 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $197.2M. The 52-week trading range was $2.56 to $15.84. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.